A Phase 2 interventional study of florbetapir F 18 and Flortaucipir F18 in Chronic Traumatic Encephalopathy, sponsored by Avid Radiopharmaceuticals. Completed at 2 sites in United States. Open to male participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-07.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Chronic Traumatic Encephalopathy with a site in United States — 6 open to participants now, 6 under way, 1 of them phase 3. Chronic Traumatic Encephalopathy · United States.
Among the 15 studies in Chronic Traumatic Encephalopathy with a site in United States, this one is one of 2 that started in 2014, is one of 3 in phase 2, and was the 4th registered.
27 studies on the registry are indexed under Chronic Traumatic Encephalopathy; 11 are open to participants now.
Browse Chronic Traumatic Encephalopathy studies →6 of the 15 studies in Chronic Traumatic Encephalopathy with a site in United States are open now. Recruiting first, the newest first:
CereMark Pharma, LLC · Sites in United States
Ages 45+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 30–90 · Healthy volunteers
OMNI Medical Services, LLC · Sites in United States
Ages 7+ · Healthy volunteers
MD Stem Cells · Sites in United States, United Arab Emirates
Ages 18+
Boston University · Sites in United States
Ages 50+ · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Chronic Traumatic Encephalopathy studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 80 across 13 interventional studies indexed under Chronic Traumatic Encephalopathy.
Median enrollment 100 across the 9 interventional studies, 143 across the 6 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Eli Lilly and Company has 1 study filed under Chronic Traumatic Encephalopathy — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Traumatic Encephalopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04124029VA Office of Research and DevelopmentContributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD) | 2026-12-31 |
| NCT02795052MD Stem CellsNeurologic Stem Cell Treatment Study | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Chronic Traumatic Encephalopathy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Flortaucipir PET scans in subjects at high risk of developing CTE (former National Football League players)
Drug: florbetapir F 18 · Drug: Flortaucipir F18
Flortaucipir PET scans in former non-contact athletes
Drug: florbetapir F 18 · Drug: Flortaucipir F18
370 megabecquerel (MBq) IV single-dose
Also known as: Amyvid, 18F-AV-45
370 megabecquerel (MBq) IV single-dose
Also known as: T807, 18F-AV-1451, LY3191748
Flortaucipir Visual Read as CTE Biomarker
Flortaucipir uptake was rated visually by sponsor expert reader as 'No Uptake', 'Mild Uptake', 'Moderate Uptake', or 'Intense Uptake'.
Time frame: Baseline scan
Relationship Between Clinical Presentation and Tau Deposition (Subjects at High Risk of CTE Only)
The relationship between flortaucipir uptake and clinical presentation, as measured by the Mini-Mental State Examination (MMSE). Mini-mental status exam is a 30-point questionnaire that is used to measure cognitive impairment. Scores range from 0 to 30 with lower scores representing greater levels of cognitive impairment. Specified in statistical analysis plan to only be conducted in High Risk of CTE group.
Time frame: baseline scan
Subjects were recruited between June 2014 and October 2015 from the DETECT study (National Institutes of Health grant R01NS078337) and the Arizona Alzheimer's Consortium ("Long-Term Consequences of Repetitive Brain Injury in Athletes: A Longitudinal Study with Eventual Brain Donation")
| Milestone | High Risk of CTE | Controls |
|---|---|---|
| Started | 30 | 11 |
| Completed | 28 | 11 |
| Not completed | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Flortaucipir uptake was rated visually by sponsor expert reader as 'No Uptake', 'Mild Uptake', 'Moderate Uptake', or 'Intense Uptake'.
| Participants | High Risk of CTE | Controls |
|---|---|---|
| No Uptake | 23 | 11 |
| Mild Uptake | 5 | 0 |
| Moderate Uptake | 0 | 0 |
| Intense Uptake | 0 | 0 |
The relationship between flortaucipir uptake and clinical presentation, as measured by the Mini-Mental State Examination (MMSE). Mini-mental status exam is a 30-point questionnaire that is used to measure cognitive impairment. Scores range from 0 to 30 with lower scores representing greater levels of cognitive impairment. Specified in statistical analysis plan to only be conducted in High Risk of CTE group.
| score on a scale | High Risk of CTE |
|---|---|
| No Uptake | 27.348 (26.625 to 28.071) |
| Mild Uptake | 26.800 (25.249 to 28.351) |
Collected over End of study for AE reporting was 48 hours after the last study drug administration.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Risk of CTE | 0/29 (0%) | 0/29 (0%) | 11/29 (37.9%) |
| Controls | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Event | High Risk of CTE | Controls |
|---|---|---|
| headacheNervous system disorders | 4/29 | 2/11 |
| muscle spasmsMusculoskeletal and connective tissue disorders | 0/29 | 2/11 |
| dizzinessNervous system disorders | 0/29 | 1/11 |
| nauseaGastrointestinal disorders | 2/29 | 0/11 |
| oral painGastrointestinal disorders | 2/29 | 0/11 |
| diarrhoeaGastrointestinal disorders | 1/29 | 0/11 |
| musculoskeletal discomfortMusculoskeletal and connective tissue disorders | 1/29 | 0/11 |
| fatigueGeneral disorders | 1/29 | 0/11 |
Includes all subjects who received at least one dose of florbetapir or flortaucipir
| Age, Continuous(years) | High Risk of CTE | Controls | Total |
|---|---|---|---|
| Mean | 58.5 ± 8.27 | 57.4 ± 6.25 | 58.2 ± 7.71 |
| Sex: Female, Male(Participants) | High Risk of CTE | Controls | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 29 | 11 | 40 |
| Ethnicity (NIH/OMB)(Participants) | High Risk of CTE | Controls | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 29 | 11 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | High Risk of CTE | Controls | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 14 | 1 | 15 |
| White | 14 | 10 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | High Risk of CTE | Controls | Total |
|---|---|---|---|
| United States | 29 | 11 | 40 |
| MMSE(units on a scale) | High Risk of CTE | Controls | Total |
|---|---|---|---|
| Mean | 27.2 ± 1.64 | 28.6 ± 0.92 | 27.6 ± 1.60 |
| Amyloid status(Participants) | High Risk of CTE | Controls | Total |
|---|---|---|---|
| Amyloid positive | 3 | 0 | 3 |
| Amyloid Negative | 25 | 11 | 36 |
The record gives a start of Jun 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 4 years 11 months after primary completion. A results delay was requested in Feb 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir
Chronic Traumatic Encephalopathy →